Angiopep-2 functionalized poly(lactic-co-glycolic acid) nanocomposite for synergistic chemo-immunotherapy in glioma through STING pathway activation
Source abstract
Abstract
Effective treatment of glioma remains challenging due to the limited permeability of the blood–brain barrier (BBB) and the highly immunosuppressive tumor microenvironment. To address these obstacles, we develop a multifunctional nanocomposite, Ang-PMT, that enables synergistic chemo-immunotherapy by enhancing BBB penetration and amplifying activation of the stimulator of interferon genes (STING) pathway. Ang-PMT consists of poly(lactic-co-glycolic acid) (PLGA) conjugated with angiopep-2 (Ang) and encapsulates manganese dioxide (MnO 2 ) nanoparticles and triphenylphosphonium modified doxorubicin (TPP-DOX). Ang-PMT efficiently traverses the BBB via Ang-mediated transcytosis and selectively targets glioma cells through mitochondrial localization conferred by the TPP moiety. Upon exposure to intracellular glutathione, Ang-PMT rapidly degrades, releasing DOX and generating Mn 2+ ions that synergistically activate STING signaling and induce immunogenic cell death, thereby amplifying therapeutic efficacy. Consequently, Ang-PMT enables precise drug delivery and achieves potent synergistic inhibition of tumor growth, significantly outperforming TPP-DOX, Ang-PM, and Ang-PT treatments.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: interferon and immune responses · Nanoplatforms for cancer theranostics · Cancer Research and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (40)
Show source-provided references
1. Cancer neuroscience: State of the field, emerging directions10.1016/j.cell.2023.02.002 ↗
2. Tumor microenvironment-responsive nanoplatforms for enhanced cancer immunotherapy: advances and synergistic strategies10.1016/j.ntm.2025.100092 ↗
3. Brain immunology and immunotherapy in brain tumours10.1038/s41568-019-0224-7 ↗
4. Primary brain tumours in adults10.1016/S0140-6736(23)01054-1 ↗
5. Glioblastoma and other Primary Brain Malignancies in adults10.1001/jama.2023.0023 ↗
6. Antigen/adjuvant‐free liposome induces adjuvant effects for enhancing cancer immunotherapy10.1002/EXP.20230115 ↗
7. Cellular functions of cGAS-STING signaling10.1016/j.tcb.2022.11.001 ↗
8. Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy10.1186/s12943-020-01250-1 ↗
9. Smart organic–inorganic copolymer nanoparticles distinguish between microglia and cancer cells for synergistic immunotherapy in glioma
10. Chimeric Exosomes Functionalized with STING Activation for Personalized Glioblastoma Immunotherapy10.1002/advs.202306336 ↗
11. Targeting innate immune pathways for cancer immunotherapy10.1016/j.immuni.2023.07.018 ↗
12. STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma10.1172/JCI175033 ↗
13. Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition10.1016/j.ccell.2022.04.009 ↗
14. The cGAS–STING pathway and cancer10.1038/s43018-022-00468-w ↗
15. cGAS-STING, an important pathway in cancer immunotherapy10.1186/s13045-020-00916-z ↗
16. Specific activation of cGAS-STING pathway by manganese-doped bioactive glasses for boosting systemic tumor immunotherapy10.1016/j.matdes.2025.113764 ↗
17. Tumor cell membrane camouflaged liposomal pharmaceuticals for cascade catalysis‐driven redox modulation and synergistic ROS/RNS antitumor therapy10.1002/VIW.20250198 ↗
18. Manganese‐Based Tumor Immunotherapy
19. Acid-responsive biocompatible hydrogel modulating tumor dna self-repair collaborated with chemotherapy for boosting STING pathway-associated immunotherapy10.1021/acs.nanolett.5c00358 ↗
20. Cascaded immunotherapy with implantable dual-drug depots sequentially releasing STING agonists and apoptosis inducers10.1038/s41467-025-56407-7 ↗
21. Enhanced antiglioma effect by a vitamin d3-inserted lipid hybrid neutrophil membrane biomimetic multimodal nanoplatform10.1021/acsnano.4c13470 ↗
22. Engineered brain‐targeting exosome for reprogramming immunosuppressive microenvironment of glioblastoma
23. Macrophage biomimetic intelligent hollow MnO2 nanoparticle for synergistic sonodynamic-immunotherapy of glioblastoma by crossing blood brain barrier10.1016/j.matdes.2024.113483 ↗
24. Multiple synergistic effects of the microglia membrane-bionic nanoplatform on mediate tumor microenvironment remodeling to amplify glioblastoma immunotherapy10.1021/acsnano.4c01253 ↗
25. Unraveling mitochondria‐targeting reactive oxygen species modulation and their implementations in cancer therapy by nanomaterials
26. Harashima, power of mitochondrial drug delivery systems to produce innovative nanomedicines10.1016/j.addr.2020.09.010 ↗
27. Mitochondria-Targeted Microneedles reverse Doxorubicin Resistance via Apoptosis-Ferroptosis Synergy10.1021/acsnano.5c06302 ↗
28. Optimizing angiopep‐2 density on polymeric nanoparticles for enhanced blood–brain barrier penetration and glioblastoma targeting: insights from in vitro and in vivo experiments
29. Double emulsions prepared by two–step emulsification: history, state-of-the-art and perspective10.1016/j.jconrel.2018.12.037 ↗
30. Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model10.3389/fimmu.2023.1297932 ↗
31. Inflammatory tumor microenvironment responsive neutrophil exosomes-based drug delivery system for targeted glioma therapy10.1016/j.biomaterials.2021.120784 ↗
32. The blood–brain barrier and blood–tumour barrier in brain tumours and metastases10.1038/s41568-019-0205-x ↗
33. Mitochondria-Targeted Multifunctional Nanoprodrugs by Inhibiting Metabolic Reprogramming for Combating Cisplatin-Resistant Lung Cancer10.1021/acsnano.4c04024 ↗
34. Mitochondrion-specific dendritic lipopeptide liposomes for targeted sub-cellular delivery10.1038/s41467-021-22594-2 ↗
35. Inhibition of Mitochondrial Biosynthesis using a “Right‐Side‐Out” Membrane‐Camouflaged Micelle to Facilitate the Therapeutic Effects of Shikonin on Triple‐Negative Breast Cancer
36. Unraveling the interaction between doxorubicin and DNA origami nanostructures for customizable chemotherapeutic drug release10.1093/nar/gkab097 ↗
37. Amplifying STING activation by cyclic dinucleotide–manganese particles for local and systemic cancer metalloimmunotherapy10.1038/s41565-021-00962-9 ↗
38. Chemotherapeutic drug-induced immunogenic cell death for nanomedicine-based cancer chemo–immunotherapy10.1039/D1NR05512G ↗
39. Nanocarrier-induced inflammation: mechanisms, immunometabolic impacts and strategies for safer design10.1016/j.tmed.2026.100002 ↗
40. A Bioinspired Nanoprobe with Multilevel Responsive T 1 ‐Weighted MR Signal‐Amplification Illuminates Ultrasmall Metastases